⌘K
t
Venture Life Group PLC announced on January 9, 2026, that CEO Jerry Randall sold 387,705 Ordinary Shares. The shares were sold at a volume-weighted average price of 66.22 pence per share between January 7-9, 2026. Following this transaction, Mr. Randall beneficially holds 2,348,828 Ordinary Shares, representing approximately 1.82% of the company's issued share capital.
| Date | 9 Jan 2026 |
| Time | 11:27:56 |
| Category | Director/PDMR dealings |
| ID | 3640O |
9 January 2026
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Director/PDMR Shareholding
Further to the announcement on 2 January 2026 of the exercise of options over 483,333 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") by Jerry Randall (Chief Executive Officer), the Company has been notified that, in order to satisfy the payment of the exercise price of the options and the personal tax liabilities resulting from the exercise of the options, Jerry Randall has sold 387,705 Ordinary Shares at a volume-weighted average price of 66.22 pence per Ordinary Share ("the "Share Sale").
Following the Share Sale, Jerry Randall beneficially holds 2,348,828 Ordinary Shares representing approximately 1.82 per cent. of the Company's issued share capital.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Jerry Randall |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
Venture Life Group plc |
||||
|
b)
|
LEI
|
213800S8CZUPLAB2KC70 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 |
||||
|
b)
|
Nature of the transaction
|
Sale of Ordinary Shares |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
- 387,705 Ordinary Shares - 66.22 pence
|
||||
|
e)
|
Date of the transaction
|
7 / 8 / 9 January 2026 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange
|
||||